Naoto Oku - Pharma

Author Information

Naoto Oku is a prominent figure in the field of pharmaceutical sciences, currently affiliated with the Department of Medical Biochemistry at the School of Pharmaceutical Sciences, University of Shizuoka, Japan. His research primarily focuses on the development and application of advanced drug delivery systems, including liposomal and nanoparticle-based therapies for various medical conditions. His work is instrumental in pushing the boundaries of treatment strategies, particularly in the realm of neuroprotective agents and biomedicine.

Research Contributions

Naoto Oku has made significant contributions to the field of drug delivery systems, with a focus on the design and application of nanoparticles and liposomes. His recent research includes exploring liposomal neuroprotective agents for ischemic stroke treatment and investigating synthetic hydrogel nanoparticles for sepsis therapy. Furthermore, his work delves into the impact of circadian rhythm disruption on cancer metastasis and the potential preventive role of dietary compounds. Naoto Oku's research has also emphasized enhancing the efficacy of lipid nanoparticles and developing innovative strategies for the treatment of diseases such as multiple sclerosis.

Aliases

Naoto Oku is also known by several aliases, including N Oku and N. Oku. These variations of his name are used across different publications and databases.

Publication and Citation Metrics

Metric	Value
Total Papers	433
Total Citations	11,770
h-index	55

Publications:

Application and Utility of Liposomal Neuroprotective Agents and Biomimetic Nanoparticles for the Treatment of Ischemic Stroke

DOI: 10.3390/pharmaceutics14020361

Year: 2022

Metastasis of Breast Cancer Promoted by Circadian Rhythm Disruption due to Light/Dark Shift and its Prevention by Dietary Quercetin in Mice

DOI: 10.5334/jcr.203

Year: 2021

Synthetic hydrogel nanoparticles for sepsis therapy

DOI: 10.1038/s41467-021-25847-2

Year: 2021

Influence of Purification Process on the Function of Synthetic Polymer Nanoparticles.

DOI: 10.1248/cpb.c21-00273

Year: 2021

Enhancement of target toxin neutralization effect in vivo by PEGylation of multifunctionalized lipid nanoparticles.

DOI: 10.1016/j.bbrc.2021.03.073

Year: 2021

New strategy for MS treatment with autoantigen-modified liposomes and their therapeutic effect.

DOI: 10.1016/j.jconrel.2021.05.027

Year: 2021

Design of synthetic polymer nanoparticles that inhibit glucose absorption from the intestine.

DOI: 10.1016/j.bbrc.2021.05.005

Year: 2021

Design of abiotic polymer ligand-decorated lipid nanoparticles for effective neutralization of target toxins in the blood.

DOI: 10.1039/d1bm00515d

Year: 2021

Synthetic hydrogel nanoparticles for sepsis therapy

DOI: 10.21203/RS.3.RS-150516/V1

Year: 2021

Charge-reversible Lipid Derivative: A Novel Type of pH-responsive Lipid for Nanoparticle-mediated siRNA Delivery.

DOI: 10.1016/j.ijpharm.2020.119479

Year: 2020

How are ADEs Detected and Reported?

Who Can Participate in Clinical Trials?

How Does Pharma Play a Role in Chronic Conditions?

What Are the Challenges in Managing Chronic Conditions?

What Role Does Regulatory Affairs Play?

What are Chronic Conditions?

What Education and Training Do Pharmacists Need?

What are Contract Research Organizations (CROs)?

What are Adverse Drug Events?

How Can ADEs be Prevented?

Partnered Content Networks

Relevant Topics